Pharmaceutical company Merck announced the results of the EVOLUTION (evolutionRMS1 and evolutionRMS2) clinical trials earlier this month. They found evobrutinib wasn’t more effective at reducing relapses than existing drug teriflunomide.
This week, researchers from across the globe gathered together at the world’s largest MS research conference. One of the hot topics at the conference was Epstein-Barr virus (EBV) – a common type of herpes virus.
A new study from the University of Edinburgh shows myelin-making cells have different characteristics depending on where they are in the body. This could explain why myelin repair is so variable, even within one person.
Several previous studies suggested experiencing depression when you have MS could be linked to increased disability later on. But a new paper from the UK MS Register hasn’t found any evidence to support that.
94 results found
Join the Research Network
Our Research Network make sure all the research we fund reflects the needs and interests of people living with MS. And they help us talk about it in a way that’s accessible to everyone.
Anyone who lives with MS or cares for someone who does can get involved. It doesn't matter where in the UK you live or how much research experience you have.